comparemela.com

Latest Breaking News On - அண்சச்சுட்ஸ் மருத்துவ - Page 5 : comparemela.com

UCHealth sending PPE, medical supplies to India amid COVID surge

“I am floored, I am humbled, I am speechless at the turnout we have gotten with this cause,” he said. The first shipment of supplies is expected to reach southern India by Tuesday. Guntupalli set up a GoFundMe to offset the shipping cost for the donations, as of this writing, has raised $27,170.  India, the world s second most populous country, reported 403,000 confirmed cases of COVID-19 on Sunday and 4,092 deaths. Hospitals there have experienced oxygen shortages due to the influx of patients.  I m overwhelmed at the love and support people of Colorado have shown for a country that most people are never going to visit in their life and have a very minimal connection to, but I think that human connection that idea that we want our kids to be safe, parents to be safe, neighbors to be safe is universal, Guntupalli said. 

CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis

CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.

New study determines cystic fibrosis therapy is safe and effective for young children

 E-Mail IMAGE: Lead study author Jordana Hoppe, MD, a pediatric pulmonologist with Children s Hospital Colorado and assistant professor of pediatrics at the University of Colorado School of Medicine on the Anschutz Medical. view more  Credit: Children s Hospital Colorado Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.